Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  The Lancet Haematology

• Publication date

  2016-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S2352-3026(16)30147-8PMID 27751707
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes

  2016cited by this paper
• Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.

  2016cited by this paper
• Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.

  2016cited by this paper
• Patient reported outcomes (PROs) of multiple myeloma (MM) patients treated with panobinostat (PAN) after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled, PANORAMA-1 trial.

  2016cited by this paper
• Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study)

  2015cited by this paper
• Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma

  2015cited by this paper
• Inflammation rapidly reorganizes mouse bone marrow B cells and their environment in conjunction with early IgM responses.

  2015cited by this paper
• Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

  2015cited by this paper
• Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up

  2015cited by this paper
• Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

  2015cited by this paper
• Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

  2014cited by this paper
• Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

  2014cited by this paper
• Time-dependent endpoints as predictors of overall survival in multiple myeloma

  2013cited by this paper
• Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

  2013cited by this paper
• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  2012cited by this paper
• A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.

  2011cited by this paper
• Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma

  2011cited by this paper
• Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

  2011cited by this paper
• In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

  2010cited by this paper
• Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.

  2010cited by this paper
• Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

  2010cited by this paper
• Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short‐lived

  2009cited by this paper
• Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

  2009cited by this paper
• Improved survival in multiple myeloma and the impact of novel therapies.

  2008cited by this paper
• Clinically relevant end points and new drug approvals for myeloma

  2008cited by this paper
• Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

  2006cited by this paper
• Clinical course of patients with relapsed multiple myeloma.

  2004cited by this paper

• The role of ER-associated degradation and ER-phagy in health and disease

  2026cites this paper
• Macrophage polarization in hematologic cancers: mechanisms and therapeutic strategies

  2026cites this paper
• The dual role of glucocorticoids in the breast cancer immune microenvironment: mechanisms and therapeutic implications

  2025cites this paper
• Adverse drug reaction profiles of histone deacetylase inhibitors

  2025cites this paper
• Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline

  2025cites this paper
• Epigenetic reprogramming in multiple myeloma—Challenges and opportunities

  2025cites this paper
• The current report on drug development focuses on "The new dimension" of cancer hallmarks.

  2025cites this paper
• A Novel Chemotherapy Combination to Enhance Proteotoxic Cell Death in Hepatocellular Carcinoma Experimental Models Without Killing Non-Cancer Cells

  2025cites this paper
• The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Potential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysis

  2025cites this paper
• Post-Translational Modifications in Multiple Myeloma: Mechanisms of Drug Resistance and Therapeutic Opportunities

  2025cites this paper
• Cyclophilin Inhibitor Rencofilstat Combined with Proteasome Inhibitor Ixazomib Increases Proteotoxic Cell Death in Advanced Prostate Cancer Cells with Minimal Effects on Non-Cancer Cells

  2025cites this paper
• Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta‐Analysis

  2025cites this paper
• Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities

  2024cites this paper
• HDAC Inhibition Induces CD26 Expression on Multiple Myeloma Cells via the c-Myc/Sp1-mediated Promoter Activation

  2024cites this paper
• Getting the right combination to break the epigenetic code

  2024influential citation
• Epigenetics-targeted drugs: current paradigms and future challenges

  2024cites this paper
• Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.

  2024cites this paper
• Diversity, Equity, and Inclusion in Multiple Myeloma: A Call to Action.

  2024cites this paper
• Pharmacological targeting of the cancer epigenome

  2024cites this paper
• Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives

  2024cites this paper
• Effects of Epigenetic Therapy on Natural Killer Cell Function and Development in Hematologic Malignancy.

  2023cites this paper
• Outcomes with panobinostat in heavily pretreated multiple myeloma patients.

  2023cites this paper
• Oncology Clinical Trials in Greece: Progress in the Past Decade.

  2023cites this paper
• Safety and efficacy of a new high‐dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high‐risk myeloma: Matched‐pair comparisons with concurrent control cohorts

  2023cites this paper
• CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma

  2023cites this paper
• Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?

  2023cites this paper
• Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis

  2023cites this paper
• Inhibition of clonal expansion of parietal epithelial cells and crescent–podocyte transition in severe glomerulonephritis: on the way to targeted therapy?

  2023cites this paper
• Past, Present, and a Glance into the Future of Multiple Myeloma Treatment

  2023cites this paper
• Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies

  2023cites this paper
• PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma

  2022cites this paper
• The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies

  2022cites this paper
• Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies

  2022cites this paper
• Recent Advancement in Anticancer Compounds from Marine Organisms: Approval, Use and Bioinformatic Approaches to Predict New Targets

  2022cites this paper
• Fitness and frailty in myeloma.

  2022cites this paper
• Daratumumab in first-line is cost-effective in transplant-eligible newly diagnosed myeloma patients.

  2022cites this paper
• Effect modification in network meta-analyses of treatments for relapsing refractory multiple myeloma (RRMM): systematic review, meta-analysis, and simulation

  2022cites this paper
• Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021.

  2022cites this paper
• Histone Modifying Enzymes in Gynaecological Cancers

  2021cites this paper
• Treatment of relapsed and refractory multiple myeloma

  2021cites this paper
• Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials

  2021cites this paper
• Genome Instability in Multiple Myeloma: Facts and Factors

  2021cites this paper
• Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM

  2021cites this paper
• Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances

  2021cites this paper
• Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond

  2021cites this paper
• Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications

  2021cites this paper
• Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.

  2021cites this paper
• Expression and prognostic analyses of HDACs in human gastric cancer based on bioinformatic analysis

  2021cites this paper
• A High-Throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma.

  2021cites this paper
• From Bench to Bedside

  2021cites this paper
• Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options.

  2021cites this paper
• Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.

  2021cites this paper
• Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma

  2021cites this paper
• The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges

  2020cites this paper
• The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review.

  2020cites this paper
• Efficacy of Panobinostat for the Treatment of Multiple Myeloma

  2020cites this paper
• Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  2020cites this paper
• Current Treatment Strategies for Multiple Myeloma.

  2020cites this paper
• Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

  2020cites this paper
• Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

  2020cites this paper
• Evolution of diagnostic workup and treatment for multiple myeloma 2013‐2019

  2020cites this paper
• Multiple myeloma: the (r)evolution of current therapy and a glance into future.

  2020cites this paper
• Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review

  2020cites this paper
• Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma

  2020cites this paper
• The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

  2020cites this paper
• Multiple myeloma: the (r)evolution of current therapy and a glance into future.

  2020cites this paper
• Approaching the first relapse after autologous transplant in multiple myeloma

  2020cites this paper
• Multiple myeloma – 2020 update on diagnosis and management

  2020cites this paper
• Sequencing multiple myeloma therapies with and after antibody therapies.

  2020cites this paper
• Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma

  2020cites this paper
• Original Versus Generic Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Comparison of Effectivity and Adverse Events.

  2020cites this paper
• Recommendations on the management of multiple myeloma in 2020

  2020cites this paper
• Targeting pan-essential genes in cancer: challenges and opportunities.

  2020cites this paper
• Myélome multiple

  2020cites this paper
• Multiple Myeloma with a Special Focus on Precision Medicine

  2020cites this paper
• Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide

  2019cites this paper
• Proteostasis in the Endoplasmic Reticulum: Road to Cure

  2019cites this paper
• Limited treatment options in refractory multiple myeloma: promising therapeutic developments

  2019cites this paper
• Cancer Stem Cells in Multiple Myeloma and the Development of Novel Therapeutic Strategies

  2019cites this paper
• Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia

  2019cites this paper
• Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities.

  2019cites this paper
• The role of CXCR4 in multiple myeloma: Cells’ journey from bone marrow to beyond

  2019cites this paper
• Therapeutic options to treat mustard gas poisoning – Review

  2019cites this paper
• Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?

  2019cites this paper
• Title: Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial)

  2019cites this paper
• Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.

  2019cites this paper
• Updates and rationale of clinical trials in multiple myeloma

  2019cites this paper
• Multiple Myeloma: Current Advances and Future Directions.

  2019cites this paper
• Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later

  2019influential citation
• Measuring Survival Benefit in Health Technology Assessment in the Presence of Nonproportional Hazards.

  2019cites this paper
• Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.

  2019cites this paper
• Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis

  2019cites this paper
• Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.

  2019cites this paper
• Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia.

  2019cites this paper
• Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets

  2019cites this paper
• Multiple Myeloma

  2019cites this paper
• Unfavourable biological prognostic factors in Multiple Myeloma

  2019cites this paper
• Key actors in cancer therapy: epigenetic modifiers

  2019cites this paper
• Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?

  2018cites this paper